Trials / Recruiting
RecruitingNCT07023627
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- Female
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB123667 | Administered orally twice daily (BID). |
Timeline
- Start date
- 2025-11-12
- Primary completion
- 2027-04-27
- Completion
- 2027-10-24
- First posted
- 2025-06-17
- Last updated
- 2026-04-14
Locations
81 sites across 8 countries: United States, Australia, Belgium, Japan, Puerto Rico, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07023627. Inclusion in this directory is not an endorsement.